Compare BIO-TECHNE Corp (TECH) vs Wix.Com Ltd (WIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BIO-TECHNE Corp vs Wix.Com Ltd — how do they compare? BIO-TECHNE Corp trades at $72.46 (market cap $11.37B), while Wix.Com Ltd trades at $74.13 (market cap $3.05B). The key difference: BIO-TECHNE Corp is far larger — about 3.7× Wix.Com Ltd's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Wix.Com Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold BIO-TECHNE Corp for 63 Days and Wix.Com Ltd for 62 Days on average.
| TECH | WIX | |
|---|---|---|
Market Cap | $11.37B | $3.05B |
Volume | 3,153,511 | 748,691 |
Sector | Health | Technology |
52-Week High | $72.61 | $145.54 |
52-Week Low | $43.31 | $40.43 |
Typical Hold Time | 63 Days | 62 Days |
Enterprise Value | $11.40B | $4.13B |
Dividend Yield | 0.44% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
Wix.com trades at $74.13, showing modest daily gains of 0.3%. The stock faces technical headwinds with a bearish moving average signal and RSI near overbought levels at 72.1. Fundamentally, revenue growth continues with 2025 reaching $1.99B, though profitability remains inconsistent with a negative net income margin of -8.19% in 2026. Analyst sentiment remains positive with 63% buy ratings and a $77 consensus target, but multiple class action lawsuits filed in September 2026 create near-term uncertainty.
Wix presents a mixed investment case with strong revenue growth offset by profitability challenges. The 3.9% upside to consensus target suggests modest near-term potential, but legal overhangs and volatile earnings create significant risk. Investors should weigh the company's market position against execution risks and legal uncertainties before establishing positions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →About Wix.Com Ltd
Wix.com Ltd is a cloud-based development platform provider for millions of registered users worldwide. The company is engaged in web development and management that provides an easy-to-use powerful cloud-based platform of products through a freemium model. Its core products consist of three web editors: the Wix Editor, intended for users with basic technological skills, Wix ADI, intended for novice users and Corvid, intended for more tech-savvy users. The company's web development technology is built based on HTML5 and offers HTML5 compatible capabilities, web design and layout tools, domain hosting, and other marketing and workflow management applications and services. The geographic segments include North America, Europe, Latin America, Asia and others.
Read more on WIX →
